The Week in Review: Nov 2 – Nov 9, 2018

Friday, Nov 9, 2018 News Recap: Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program. High Prevalence of Cirrhosis in Adults with Chronic...

High Prevalence of Cirrhosis in Adults With Chronic HBV at a Safety-Net Hospital

Of adults with chronic hepatitis B virus (HBV) infection seen at a safety-net hospital, nearly 30% had cirrhosis at initial presentation, with older male patients being at the highest risk, according to a retrospective study published in the Journal of Clinical and Experimental Hepatology. Cirrhosis is a serious consequence of HBV infection that is associated with a financial burden of $13 billion in the United States. Delays in HBV and cirrhosis diagnosi